130 results on '"van 't Hof, Arnoud W.J."'
Search Results
2. Medically Treated Nonischemic Thin-Cap Fibroatheroma Lesions Versus Fractional Flow Reserve-Guided Complete Revascularization in Diabetic Patients
3. Percutaneous coronary intervention with drug-eluting stents versus coronary bypass surgery for coronary artery disease: A Bayesian perspective
4. Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study
5. Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
6. Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
7. Meta-Analysis Evaluating High-Sensitivity Cardiac Troponin T Kinetics after Coronary Artery Bypass Grafting in Relation to the Current Definitions of Myocardial Infarction
8. Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI
9. NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial
10. MINOCA: The caveat of absence of coronary obstruction in myocardial infarction
11. Value of Prehospital Troponin Assessment in Suspected Non-ST-Elevation Acute Coronary Syndrome
12. Comparison of Outcomes and Intervention Among Patients With Non–ST-Segment Elevation Acute Myocardial Infarction of Those With a Left Circumflex Versus Those With a Non–Left Circumflex-Related Coronary Artery (From the ELISA-3 Trial)
13. One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent
14. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
15. 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry
16. CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
17. Impact of ischemic time on post-infarction left ventricular function in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
18. Risk of bleeding after prehospital administration of high dose tirofiban for ST Elevation Myocardial Infarction
19. Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial
20. Prehospital triage in the ambulance reduces infarct size and improves clinical outcome
21. Impact of diabetes on outcome in patients with non-ST-elevation myocardial infarction
22. Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
23. Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: Correlates of reperfusion before primary PCI
24. The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy
25. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future
26. Primary percutaneous coronary intervention for ST-elevation myocardial infarction: From clinical trial to clinical practice
27. Comparison of Usefulness of C-reactive Protein Versus White Blood Cell Count to Predict Outcome After Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction
28. Added value of modified transoesophageal echocardiography in the diagnosis of atherosclerosis of the distal ascending aorta in cardiac surgery patients
29. Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI
30. Point-of-care high-sensitivity troponin-I analysis in capillary blood for acute coronary syndrome diagnostics.
31. Prognostic importance of troponin T and creatine kinase after elective angioplasty
32. Mortality in Patients With Left Ventricular Ejection Fraction ≤30% After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
33. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study
34. Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention
35. Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction
36. Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction
37. ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion
38. Successful reperfusion for acute ST elevation myocardial infarction is associated with a decrease in WBC count
39. Effect of Coronary Occlusion Site on Angiographic and Clinical Outcome in Acute Myocardial Infarction Patients Treated With Early Coronary Intervention
40. The Effect of Pre-Hospital Glycoprotein IIB–IIIA Inhibitors on Angiographic Outcome in STEMI Patients who are Candidates for Primary PCI
41. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes
42. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study
43. Old Age and Outcome After Primary Angioplasty for Acute Myocardial Infarction
44. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
45. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors
46. Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI: Focus on Tirofiban
47. Ventricular fibrillation in acute myocardial infarction before and during primary PCI
48. The challenge of reducing time to reperfusion in patients with acute ST elevation myocardial infarction
49. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
50. Prognostic importance of creatine kinase and creatine kinase-MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.